Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registry.
Adult
Arthritis, Rheumatoid
/ drug therapy
Axial Spondyloarthritis
/ epidemiology
Biological Products
/ therapeutic use
Comorbidity
Female
Humans
Latent Tuberculosis
/ diagnosis
Male
Middle Aged
Morocco
/ epidemiology
Prevalence
Registries
Retrospective Studies
Tuberculin Test
/ statistics & numerical data
Latent tuberculosis infection
Moroccan biotherapy registry
Rheumatoid arthritis
Spondyloarthritis
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
15
05
2021
accepted:
18
06
2021
pubmed:
27
6
2021
medline:
6
1
2022
entrez:
26
6
2021
Statut:
ppublish
Résumé
Before the initiation of biotherapy in the treatment of rheumatic diseases, it is highly recommended for the patients to be screened for latent tuberculosis infection (LTBI). The objective of this study is to identify the prevalence of LTBI among patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) before the initiation of biologic therapy in the Moroccan biotherapy registry (RBSMR). A cross sectional study was conducted using the baseline data of the Moroccan biotherapy registry. Tuberculin skin test or IGRA test or both tests were done before starting anti-TNF treatment for screening LTBI. The comparisons between positive and negative LTBI patients according to rheumatic disease were examined using categorical comparisons. 259 patients were included in this study.94 patients had RA and 165 had SpA. The mean age of the RA patients was 50.49 ± 11.82 years with a majority of females (84%). The mean age for the SpA patients was 36 ± 13.7 years with a majority of males (67.3%). The prevalence of LTBI in the RBSMR was 21.6%. This prevalence was at 24.8% in SpA patients, while it was at 15.9% for RA patients. After the comparison between positive and negative LTBI patients according to rheumatic disease, no demographic, clinical, or therapeutic characteristics were statistically associated with LTBI. This study found that in an endemic TB country like Morocco, a high prevalence of patients with SpA and RA had LTBI, and that RA patients had a lower prevalence than SpA patients.
Identifiants
pubmed: 34173843
doi: 10.1007/s00296-021-04929-w
pii: 10.1007/s00296-021-04929-w
doi:
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1625-1631Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
World Health Organization (2019) Global tuberculosis report 2019. Available at: www.who.int
World Health Organization (2018) Latent tuberculosis infection—updated and consolidated guidelines for programmatic management. WHO, Switzerland
World Health Organization (2018) Global tuberculosis report 2018. Available from: www.who.int
Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D et al (2009) LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 33(5):956–973
doi: 10.1183/09031936.00120908
Ishiguro T, Takayanagi N, Kagiyama N, Yanagisawa T, Sugita Y (2014) Characteristics of tuberculosis in patients with rheumatoid arthritis: a retrospective single-center study. Intern Med 53(12):1291–1298. https://doi.org/10.2169/internalmedicine.53.1936
doi: 10.2169/internalmedicine.53.1936
pubmed: 24930647
Baronnet L, Barnetche T, Kahn V, Lacoin C, Richez CST, Schaeverbeke T (2011) Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review. Joint Bone Spine 78(3):279–284. https://doi.org/10.1016/j.jbspin.2010.12.004
doi: 10.1016/j.jbspin.2010.12.004
pubmed: 21273108
Alawneh KM, Ayesh MH, Khassawneh BY, Saadeh SS, Smadi M, Bashaireh K (2014) Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis. Biologics 8:193–198. https://doi.org/10.2147/BTT.S59574
doi: 10.2147/BTT.S59574
pubmed: 24790412
pmcid: 4003144
Goletti D, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F (2018) Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Reviw Anti Infect Ther 16(6):501–512. https://doi.org/10.1080/14787210.2018.1483238
doi: 10.1080/14787210.2018.1483238
Bergot E, Abiteboul D, Andréjak C, Antoun F et al (2018) Practice recommendations for the use and interpretation of interferon gamma release assays in the diagnosis of latent and active tuberculosis. Revue des Mal Respir 35(8):852–858
doi: 10.1016/j.rmr.2018.08.007
Hmamouchi I, Abouqal R, AchemlalAllaliBahiri LFR et al (2019) The Moroccan registry of biological therapies in rheumatic diseases (RBSMR): methods and preliminaries results. Rev Mar Rhum 49:32–37
Manuel de référence du système d'information sanitaire du programme national de lutte antituberculeuse, direction de l’épidémiologie et de lutte contre les maladies 2016. Available at www.sante.gov.ma
WHO (1963) The WHO standard tuberculin test [cited 1 June 2018]. Available from: http://apps.who.int/iris/handle/10665/112241
(2008) Rev. Mal. Respir. L'intradermo-réaction à la tuberculine (IDR) ou test à la tuberculine. 20(6–C2):7S27
Garziera G, Morsch AL, Otesbelgue F et al (2017) Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents. Clin Rheumatol 36(8):1891–1896. https://doi.org/10.1007/s10067-017-3714-6
doi: 10.1007/s10067-017-3714-6
pubmed: 28589321
de Ponce LD, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R et al (2005) Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum dis 64:1360–1361
doi: 10.1136/ard.2004.029041
Agarwal S, Das SK, Agarwal GG, Srivastava R (2014) Steroids decrease prevalence of positive tuberculin skin test in rheumatoid arthritis: implications on anti-TNF therapies. Interdiscip Perspect Infect Dis 2014:430134
doi: 10.1155/2014/430134
Koker IH, Pamuk ON, Karlikaya C, Tuncbilek N, Cakir N (2007) A low prevalence of purified protein derivative test positivity in Turkish patients with rheumatoid arthritis. Association with clinical features and HRCT findings. Clin Exp Rheumatol 25:54–59
pubmed: 17417991
Eddaoudi M, Rostom S, Hmamouchi I, El Binoune I, Amine B et al (2021) The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies. Pan Afr Med 38:183. https://doi.org/10.11604/pamj.2021.38.183.27081
doi: 10.11604/pamj.2021.38.183.27081
Cantini F, Niccoli L, Goletti D (2014) Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries. J Rheumatol Suppl 91:56–64
doi: 10.3899/jrheum.140103
Jeong DH, Kang J, Jung YJ, Yoo B, Lee C-K, Kim Y-G et al (2018) Comparison of latent tuberculosis infection screening strategies before tumor necrosis factor inhibitor treatment in inflammatory arthritis: IGRA-alone versus combination of TST and IGRA. PLoS ONE 13(7):e0198756. https://doi.org/10.1371/journal.pone.0198756
doi: 10.1371/journal.pone.0198756
pubmed: 29975703
pmcid: 6033383
Malaviya AN, Aggarwal VK, Rawat R, Baghel S, Thakran R, Zaheer Q, Garg S, Kapoor S (2018) Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in India, a high-burden TB country: the importance of Mantoux and Quantiferon-TB Gold tests. Int J Rheum Dis 21(8):1563–1571. https://doi.org/10.1111/1756-185X.13261
doi: 10.1111/1756-185X.13261
pubmed: 29345081
Singh JA, Furst DE, Bharat A, Curtis JR et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64(5):625–639. https://doi.org/10.1002/acr.21641
doi: 10.1002/acr.21641